Shorter Treatment Regimen For Drug-Resistant TB As Effective As Standard 2-Year Course, Study Shows

Health-e News: Shorter cure for resistant TB
“Drug-resistant tuberculosis (TB) can be cured in less than half the time, cutting costs and improving the chances that patients will complete the grueling treatment, according to a study published in the New England Journal of Medicine. Published on Wednesday night, the much-anticipated final results of the trial known as STREAM found that a nine- to 11-month treatment course is just as effective as the previous standard of 20 to 24 months of drugs in curing patients with multi-drug resistant TB (MDR-TB). This follows the December 2018 World Health Organization (WHO) recommendation for this shortened regimen, which, until now, was based on ‘very low certainty in the evidence’…” (Green, 3/14).

Additional coverage of the study results is available from Agence France-Presse and The Telegraph.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.